Nicotinamide Riboside (NR)
“In a phase 2 double-blind randomized controlled trial of 60 Alzheimer’s disease patients, treatment with combined metabolic activators (CMA) that included 1 g of NR, 12.35 g of L-serine, 2.55 g of Nacetylcysteine, and 3.73 g of L-carnitine tartrate was tested (Yulug et al., 2023). The CMA was dissolved in water and taken orally—1 dose daily for the first 28 days and twice daily thereafter until day 84.
“CMA treatment showed a significant improvement in cognitive function measured by ADAS-Cog, with a 26% improvement on day 28 (p=0.0000003) and a 29% improvement on day 84 (p=0.00001) compared to baseline.”
https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Nicotinamide_Riboside_UPDATE.pdf
NOTE: That was the most positive thing I saw by glancing at the document. My quote should not be relied upon as medical advice. The document is almost three years old. The clinical trials are quite likely to be complete.
Thank you for this.